First SGLT2 inhibitor approved to treat diabetic kidney disease

Canagliflozin (Invokana) can now be prescribed to slow the progression of kidney disease in patients with type II diabetes.

by Chloe Harman
SGLT2 inhibitors reduce reabsorption of filtered glucose by the kidneys, increasIng urinary glucose excretion and thereby lowering elevated plasma glucose levels. | GETTY IMAGES
SGLT2 inhibitors reduce reabsorption of filtered glucose by the kidneys, increasIng urinary glucose excretion and thereby lowering elevated plasma glucose levels. | GETTY IMAGES

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package